AR031486A1 - Derivados de pirimidina - Google Patents

Derivados de pirimidina

Info

Publication number
AR031486A1
AR031486A1 ARP010105423A ARP010105423A AR031486A1 AR 031486 A1 AR031486 A1 AR 031486A1 AR P010105423 A ARP010105423 A AR P010105423A AR P010105423 A ARP010105423 A AR P010105423A AR 031486 A1 AR031486 A1 AR 031486A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
independently
trifluoromethyl
receptor
Prior art date
Application number
ARP010105423A
Other languages
English (en)
Inventor
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR031486A1 publication Critical patent/AR031486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de formula general (1), en donde R1 es alquilo inferior, alcoxilo inferior, pirdinilo, pirimidinilo, fenilo, -S-alquilo inferior, S(O)2-alquilo inferior, -N(R)-(CH2)n-N(R)2, -O-(CH2)n-N(R)2, -N(R)2, o una amina terciaria cíclica del grupo (2) que puede contener un heteroátomo adicional, seleccionado de N, O o S, y en donde este grupo debe estar conectado con el anillo pirimidina a través del conector -O(CH2)n-; R2 es hidrogeno, alquilo inferior, alcoxilo inferior, halogeno o trifluorometilo; R3/R3' es, independientemente uno del otro, hidrogeno o alquilo inferior; R4 es, independientemente uno del otro, halogeno, trifluorometilo o alcoxilo inferior, R5 es hidrogeno o alquilo inferior; R es, independientemente uno del otro, hidrogeno o alquilo inferior; X es -C(O)N(R)- o -N(R)C(O)-; Y es -O-, -S-, SO2-, o -N(R)-; n es 1, 2, 3 o 4; y m es 0, 1 o 2; y las sales de adicion ácida farmacéuticamente aceptables de los mismos. Que tienen una gran afinidad para el receptor de NK1 y son por lo tanto, adecuados en el tratamiento de enfermedades, relacionadas con el receptor.
ARP010105423A 2000-11-22 2001-11-21 Derivados de pirimidina AR031486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00125529 2000-11-22

Publications (1)

Publication Number Publication Date
AR031486A1 true AR031486A1 (es) 2003-09-24

Family

ID=8170446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105423A AR031486A1 (es) 2000-11-22 2001-11-21 Derivados de pirimidina

Country Status (31)

Country Link
US (1) US6787539B2 (es)
EP (1) EP1339698A2 (es)
JP (1) JP3993100B2 (es)
KR (1) KR100571337B1 (es)
CN (1) CN1309710C (es)
AR (1) AR031486A1 (es)
AU (2) AU2792102A (es)
BG (1) BG107840A (es)
BR (1) BR0115480A (es)
CA (1) CA2429570A1 (es)
CZ (1) CZ20031666A3 (es)
EC (1) ECSP034619A (es)
GT (1) GT200100232A (es)
HK (1) HK1078079A1 (es)
HR (1) HRP20030362A2 (es)
HU (1) HUP0303045A3 (es)
IL (2) IL155705A0 (es)
JO (1) JO2307B1 (es)
MA (1) MA26967A1 (es)
MX (1) MXPA03004453A (es)
NO (1) NO324865B1 (es)
NZ (1) NZ525555A (es)
PA (1) PA8533501A1 (es)
PE (1) PE20020760A1 (es)
PL (1) PL366394A1 (es)
RU (1) RU2284997C2 (es)
SK (1) SK7612003A3 (es)
UY (1) UY27034A1 (es)
WO (1) WO2002042280A2 (es)
YU (1) YU39503A (es)
ZA (1) ZA200303517B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
JP4613501B2 (ja) 2004-03-17 2011-01-19 味の素株式会社 ５−保護アミノピリミジン化合物の製造方法
JP4501015B2 (ja) 2004-03-17 2010-07-14 味の素株式会社 アミノピリミジン化合物の製造方法
JP2007534941A (ja) * 2004-04-22 2007-11-29 ザイゴ　コーポレーション 光学干渉計システムおよび光学干渉計システムを用いる方法
EP1745033A4 (en) * 2004-05-08 2009-08-26 Neurogen Corp 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
US20100105688A1 (en) 2007-01-24 2010-04-29 Glaxo Group Limited Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
KR101032186B1 (ko) * 2008-12-31 2011-05-02 엘에스산전 주식회사 정격 미세 조정이 가능한 과전류 계전기
WO2011053705A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Pyrimidine compounds as delta opioid receptor modulators
WO2011053701A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57131771A (en) * 1981-02-10 1982-08-14 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
FR2536071B1 (fr) * 1982-11-12 1986-07-11 Sanofi Sa Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0799617A3 (en) 1986-02-24 1997-11-12 Mitsui Petrochemical Industries, Ltd. Therapeutic agent for neurological diseases
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SK283070B6 (sk) 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4

Also Published As

Publication number Publication date
CA2429570A1 (en) 2002-05-30
MA26967A1 (fr) 2004-12-20
YU39503A (sh) 2006-05-25
IL155705A (en) 2008-11-26
GT200100232A (es) 2002-07-04
US6787539B2 (en) 2004-09-07
PL366394A1 (en) 2005-01-24
JO2307B1 (en) 2005-09-12
EP1339698A2 (en) 2003-09-03
KR100571337B1 (ko) 2006-04-17
JP3993100B2 (ja) 2007-10-17
WO2002042280A3 (en) 2002-08-22
RU2003117481A (ru) 2005-02-20
JP2004514673A (ja) 2004-05-20
UY27034A1 (es) 2002-06-20
HK1078079A1 (en) 2006-03-03
CZ20031666A3 (cs) 2004-02-18
SK7612003A3 (en) 2004-05-04
CN1309710C (zh) 2007-04-11
RU2284997C2 (ru) 2006-10-10
NO20032291L (no) 2003-05-21
ZA200303517B (en) 2004-08-10
ECSP034619A (es) 2003-06-25
IL155705A0 (en) 2003-11-23
WO2002042280A2 (en) 2002-05-30
NO20032291D0 (no) 2003-05-21
KR20030060940A (ko) 2003-07-16
CN1628103A (zh) 2005-06-15
AU2002227921B2 (en) 2006-02-16
HRP20030362A2 (en) 2005-04-30
HUP0303045A2 (hu) 2003-12-29
BG107840A (bg) 2004-01-30
BR0115480A (pt) 2003-10-21
HUP0303045A3 (en) 2004-03-29
AU2792102A (en) 2002-06-03
US20020099207A1 (en) 2002-07-25
PE20020760A1 (es) 2002-08-21
NZ525555A (en) 2004-10-29
NO324865B1 (no) 2007-12-17
MXPA03004453A (es) 2003-08-19
PA8533501A1 (es) 2002-10-31

Similar Documents

Publication Publication Date Title
AR029717A1 (es) Derivados del pro-farmaco de 4-fenil-piridina
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
MY141597A (en) 2,4-disubstituted thiazolyl derivatives
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR035665A1 (es) Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
CY1105035T1 (el) Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
HUP0204587A2 (en) 6-position substituted indoline, production and use thereof as a medicament
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
UY28578A1 (es) Derivados de amida
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
HRP20050708A2 (en) Piperidine-benzenesulfonamide derivatives
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
AR031486A1 (es) Derivados de pirimidina
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
AR051094A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
AR036041A1 (es) Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
AR051686A1 (es) Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal